

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

NDA 21-501

CHEMISTRY REVIEW(S)

NDA 21-501

**Capital Soleil
Anthelios
UV Expert**

b(4)

b(4)

**(Avobenzene, Ecamsule, and Octocrylene Topical Cream)
(avobenzene 2%, ecamsule 3%, and octocrylene 10%)**

L'Oreal USA Products, Inc.

**Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products**

Sue-Ching Lin

Review Chemist

**Office of New Drug Quality Assessment
Pre-Marketing Division II, Branch III**

Chemistry Review Data Sheet

1. NDA 21-501
2. REVIEW #: 2
3. REVIEW DATE: 05-July-2006
4. REVIEWER: Sue-Ching Lin
5. PREVIOUS DOCUMENTS:

Submissions Reviewed in Chemistry Review #1	Document Date
Original submission	16-May-2005
Amendment (BZ)	05-Aug-2005
Amendment (BC)	11-Jan-2006
Amendment (BC)	17-Feb-2006

6. SUBMISSION(S) BEING REVIEWED:

Subjects of this Review	Document Date
Resubmission (AZ)	18-May-2006
Amendment (BC)	12-Apr-2006
Amendment (BC)	22-Jun-2006

7. NAME & ADDRESS OF APPLICANT:

Name: L'Oreal USA Products, Inc.
 Address: 111 L'Oreal Way
 Clark, New Jersey 07066
 Representative: Jean R. Grieve
 Assistant Vice President, Drug Approval Group
 Telephone: 732-680-5562

CHEMISTRY REVIEW

Chemistry Review Data Sheet

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Names: The following 5 proprietary names were proposed (names in parentheses denote marketing division):

Capital Soleil (Vichy)
Anthelios (La Roche-Posay)
UV Expert (Lancôme)

b(4)

b) Non-Proprietary Name: avobenzone, ecamsule, and octocrylene topical cream

c) Code Name/# (ONDQA only): — SPF 15 Water Resistant Cream, L'Oreal's internal formulation number 760-006

b(4)

d) Chem. Type/Submission Priority (ONDQA only):

- Chem. Type: 1 (new molecular entity) or 5 (new formulation, per the new MAPP 7500.3), depending on which NDA (21-501 or 21-502) gets approval first.

- Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505(b)(1)

10. PHARMACOL. CATEGORY: sunscreen

11. DOSAGE FORM: cream

12. STRENGTH/POTENCY: avobenzone 2%, ecamsule 3%, octocrylene 10%

13. ROUTE OF ADMINISTRATION: topical

14. Rx/OTC DISPENSED: ___ Rx x OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):

___ SPOTS product – Form Completed

x Not a SPOTS product

Chemistry Review Data Sheet


16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Avobenzone


1-(p-tert-butylphenyl)-3-(p-methoxyphenyl)-1,3-propanedione

C₂₀H₂₂O₃, MW 310.40, CAS 70356-09-1, other designation:

b(4)

Ecamsule


(±)-(3E,3'E)-3,3'-(p-Phenylenedimethyldiylidene)bis(2-oxo-10-bornanesulfonic acid)

C₂₈H₃₄O₈S₂, MW 562.3, CAS 92761-26-7, other designation: Mexoryl[®] SXOctocrylene

2-Propenoic acid, 2-cyano-3,3-diphenyl, 2-ethylhexyl ester

C₂₄H₂₇NO₂, MW 361.49, CAS 6197-30-4, Other designation:

b(4)



Chemistry Review Data Sheet

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
✓	II	[Redacted]	[Redacted]	1	adequate	22-Feb-2006	
✓	II			1	adequate	16-Dec-2005	
✓	II			1	adequate	15-Feb-2006	
✓	II			1	adequate	17-Feb-2006	
✓	IV			4	N/A		
✓	III			4	N/A		*
✓	III			4	N/A		*
✓	III			4	N/A		*
✓	III			4	N/A		*
✓	III			4	N/A		*

b(4)

*See page 54 of Chemistry Review #1 under container closure system for details

¹ Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 – Type 1 DMF

3 – Reviewed previously and no revision since last review

4 – Sufficient information in application

5 – Authority to reference not granted

6 – DMF not available

7 – Other (explain under “Comments”)

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	59,126	SPF 15 W/R
NDA	21-502	SPF 15 Daily Sunscreen Cream
NDA	21-471	SPF 20 Water Resistant Cream

b(4)

CHEMISTRY REVIEW

Chemistry Review Data Sheet

18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	N/A		
EES	Acceptable	3/16/06	S. Adams
Pharm/Tox	N/A		
Clinical Pharmacology	N/A		
LNC	N/A		
Methods Validation	Not required per current ONDQA policy*		
Office of Drug Safety	Acceptable**	12/9/05	Tina Tezky, Michael Koenig**
EA	Categorical exclusion (see review)		
Microbiology	Approval	11/30/05	Stephen Langille

*The analytical procedures and their validations were reviewed and found to be adequate. Methods validation packages will not be sent to FDA laboratories because the methods do not meet the "method validation request criteria" according to the current ONDQA policy that was announced on 1/12/05.

**The proposed proprietary names were consulted to the Division of Medication Errors and Technical Support (DMETS) in the Office of Drug Safety (consults sent by Elaine Abraham, the Project Manager). The DMETS' 12/9/05 review states that DMETS does not recommend the use of the proprietary name

Abraham (the project manager), DMETS gave the Office of Nonprescription Drugs (ONP) the option of going with the names or not, during a recent meeting between DMETS and ONP. The ONP's decision can be seen in the 2/21/06 labeling review by Dr. Michael Koenig, the ONP labeling reviewer, which indicates that all the proposed trade names are acceptable (see page 3 of the labeling review in DFS).

b(4)

**APPEARS THIS WAY
ON ORIGINAL**

The Chemistry Review for NDA 21-501

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a chemistry review perspective, this NDA is recommended for approval.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

(1) Drug Substances

The drug product contains three drug substances: avobenzone, ecamsule, and octocrylene. Avobenzone and octocrylene are active ingredients included in the over-the-counter (OTC) sunscreen monographs (21 CFR 352.10 and 352.20). These two drug substances are also USP monograph substances.

Ecamsule is a new molecular entity. It was included in the drug product in

Detailed information on the drug substances is referenced to their respective DMFs, which have been reviewed by this reviewer and found to be adequate to support this NDA.

Executive Summary Section

(2) Drug Product

The drug product is a sunscreen containing 2% of avobenzone, 3% of ecamsule, and 10% of octocrylene. The active ingredients were selected to provide a broad protection from UVA (320 to 400 nm) and UVB (290 to 320 nm) irradiation wavelengths. The absorption bands are as follows: avobenzone from 320 to 400 nm, octocrylene from 250 to 370 nm, and ecamsule from 290 to 400 nm.

The drug product also contains — excipients that provide functions such as _____ This
 sunscreen is water resistant due to _____

b(4)

b(4)

The drug product is packaged in a 100-mL tube with an _____ head and a _____ snap-top closure.

b(4)

B. Description of How the Drug Product is Intended to be Used

The drug product is intended to be applied topically for the prevention of sunburn _____
 _____ due to chronic sun exposure. It is proposed to be available over-the-counter.
 The sunscreen is applied 15 minutes before sun exposure. It may be reapplied as needed
 or after towel drying, swimming, or perspiring.

b(4)

The sunscreen is to be stored at 20-25°C. The submitted drug product stability data
 include long-term stability data for _____ months and accelerated stability data for 6 months b(4)
 on three primary stability batches manufactured at the proposed commercial
 manufacturing site. An expiration dating period of 30 months is granted for the drug
 product based on the stability data.

Executive Summary Section

C. Basis for Approvability or Not-Approval Recommendation

As stated in the executive summary of chemistry review #1 of this NDA, the only pending CMC issue was the establishment inspection. This issue was resolved on March 16, 2006, when the Office of Compliance gave an "acceptable" recommendation for all the facilities used in the manufacture and control of the drug substance and drug product.

The applicant submitted an amendment on 4/12/06 proposing to add _____ for the ecamsule impurities in the drug product impurity test (method number _____). The applicant later submitted the 6/22/06 amendment to eliminate _____ r. Instead, a revised drug product specification was submitted with changes in the acceptance criteria for the ecamsule impurities. The revision appears to be acceptable, based on the historical toxicology/clinical batch data.

The CMC information regarding the drug substance and drug product is adequate to support the over-the-counter use of this drug product, a sunscreen.

III. Administrative

- A. Reviewer's Signature electronically signed in DFS
- B. Endorsement Block electronically signed in DFS
- C. CC Block electronically signed in DFS

2 Page(s) Withheld

Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Sue Ching Lin
7/7/2006 02:16:12 PM
CHEMIST

Moo-Jhong Rhee
7/7/2006 02:54:50 PM
CHEMIST
Chief, Branch III



NDA 21-501

—
**Capital Soleil
Anthelios
UV Expert**
—

b(4)

b(4)

(Avobenzone, Ecamsule, and Octocrylene Topical Cream)
(avobenzone 2%, ecamsule 3%, and octocrylene 10%)

L'Oreal USA Products, Inc.

Sue-Ching Lin

Review Chemist

**Office of New Drug Quality Assessment
Pre-Marketing Division II, Branch III
for
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products**



Table of Contents

Chemistry Review Data Sheet.....4

The Executive Summary9

I. Recommendations.....9

A. Recommendation and Conclusion on Approvability.....9

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable9

II. Summary of Chemistry Assessments9

A. Description of the Drug Product(s) and Drug Substance(s)9

B. Description of How the Drug Product is Intended to be Used.....10

C. Basis for Approvability or Not-Approval Recommendation11

III. Administrative.....11

A. Reviewer’s Signature11

B. Endorsement Block.....11

C. CC Block.....11

Chemistry Assessment12

I. DRUG SUBSTANCES.....12

A. Description & Characterization13

B. Manufacturers.....14

C. Synthesis / Method Of Manufacture15

D. Process Controls.....15

E. Reference Standard15

F. Regulatory Specifications / Analytical Methods16

1. Drug Substance Specifications.....16

2. Analytical Procedures.....18

3. Validation of Analytical Procedures.....23

4. Batch Analysis25

5. Dual Source Comparison of Avobenzone.....26

G. Container/Closure System For Drug Substance Storage.....26

H. Drug Substance Stability26

II. DRUG PRODUCT27

A. Components/Composition28



Table of Contents

B. Specifications & Methods For Drug Product Ingredients	29
1. Active Ingredient(s).....	29
2. Inactive Ingredients	29
C. Manufacturer	31
D. Methods Of Manufacturing And Packaging	32
1. Production Operations	32
2. In-Process Controls & Tests.....	35
3. Reprocessing Operations.....	36
E. Regulatory Specifications And Methods For Drug Product.....	37
1. Drug Product Specification	37
2. Analytical Procedures.....	40
3. Validation of Analytical Methods	49
F. Container/Closure System.....	54
G. Microbiology.....	58
H. Drug Product Stability	58
III. INVESTIGATIONAL FORMULATIONS	62
IV. ENVIRONMENTAL ASSESSMENT.....	62
V. METHODS VALIDATION	63
VI. LABELING	63
VII. ESTABLISHMENT INSPECTION.....	64
VIII. DRAFT DEFICIENCY LETTER.....	64

Chemistry Review Data Sheet

1. NDA 21-501
2. REVIEW #: 1
3. REVIEW DATE: 23-Feb-2006
4. REVIEWER: Sue-Ching Lin
5. PREVIOUS DOCUMENTS:

<u>Previous Documents</u>	<u>Document Date</u>
End-of Phase 2 meeting (IND 59,126)	24-Jan-2001
Stability Matrix Design agreement	19-Apr-2001
Pre-NDA meeting	18-Sep-2001
Pre-NDA meeting follow-up	03-Dec-2001
FDA comments on viscosity presentation	04-Dec-2001
FDA fax providing comments on stability data	17-Jan-2002
Telecon discussing definition of cream and lotion	02-Apr-2002
FDA fax regarding CMC issues	13-Sep-2002

6. SUBMISSION(S) BEING REVIEWED:

<u>Submission(s) Reviewed</u>	<u>Document Date</u>
Original submission	16-May-2005
Amendment (BZ)	05-Aug-2005
Amendment (BC)	11-Jan-2006
Amendment (BC)	17-Feb-2006

7. NAME & ADDRESS OF APPLICANT:

Name:	L'Oreal USA Products, Inc.
Address:	111 L'Oreal Way Clark, New Jersey 07066
Representative:	Jean R. Grieve Assistant Vice President, Drug Approval Group
Telephone:	732-680-5562

Chemistry Review Data Sheet

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Names: The following 5 proprietary names were proposed (names in parentheses denote marketing division):

Capital Soleil (Vichy)
 Anthelios (La Roche-Posay)
 UV Expert (Lancôme)

b(4)

b(4)

b) Non-Proprietary Name: avobenzone, ecamsule, and octocrylene topical cream

c) Code Name/# (ONDC only): — SPF 15 Water Resistant Cream, L'Oreal's internal formulation number 760-006

b(4)

d) Chem. Type/Submission Priority (ONDC only):

- Chem. Type: 1 (new molecular entity) or 5 (new formulation, per the new MAPP 7500.3), depending on which NDA (21-501 or 21-502) gets approval first.
- Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505(b)(1)

10. PHARMACOL. CATEGORY: sunscreen

11. DOSAGE FORM: cream

12. STRENGTH/POTENCY: avobenzone 2%, ecamsule 3%, octocrylene 10%

13. ROUTE OF ADMINISTRATION: topical

14. Rx/OTC DISPENSED: ___ Rx x OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):

___ SPOTS product – Form Completed


x Not a SPOTS product

Chemistry Review Data Sheet

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Avobenzone


1-(p-tert-butylphenyl)-3-(p-methoxyphenyl)-1,3-propanedione

C₂₀H₂₂O₃, MW 310.40, CAS 70356-09-1, other designation: _____


b(4)

Ecamsule

(±)-(3E,3'E)-3,3'-(p-Phenylenedimethylidene)bis(2-oxo-10-bornanesulfonic acid)

C₂₈H₃₄O₈S₂, MW 562.3, CAS 92761-26-7, other designation: Mexoryl® SXOctocrylene

2-Propenoic acid, 2-cyano-3,3-diphenyl, 2-ethylhexyl ester

C₂₄H₂₇NO₂, MW 361.49, CAS 6197-30-4, Other designation: _____

b(4)

Chemistry Review Data Sheet

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
/	II		/	1	adequate	22-Feb-2006	
/	II			1	adequate	16-Dec-2005	
/	II			1	adequate	15-Feb-2006	
/	II			1	adequate	17-Feb-2006	
/	IV			4	N/A		
/	III			4	N/A		*
/	III			4	N/A		*
/	III			4	N/A		*
/	III			4	N/A		*
/	III			4	N/A		*

b(4)

*See page 54 of this review under container closure system for details

¹ Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 – Type 1 DMF

3 – Reviewed previously and no revision since last review

4 – Sufficient information in application

5 – Authority to reference not granted

6 – DMF not available

7 – Other (explain under “Comments”)

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	59,126	SPF 15 W/R
NDA	21-502	SPF 15 Daily Sunscreen Cream
NDA	21-471	SPF 20 Water Resistant Cream

b(4)



CHEMISTRY REVIEW



Chemistry Review Data Sheet

18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	N/A		
EES	Pending*		
Pharm/Tox	N/A		
Clinical Pharmacology	N/A		
LNC	N/A		
Methods Validation	Not required per current ONDQA policy**		
Office of Drug Safety	Acceptable***	12/9/05	Tina Tezky, Michael Koenig**
EA	Categorical exclusion (see review)		
Microbiology	Approval	11/30/05	Stephen Langille

* All the manufacturing and control facilities are acceptable, with the exception of _____ (the new avobenzone manufacturing site). The inspection of _____ scheduled for March 13-16, 2006 (the due date of this NDA is March 16, 2006).

**The analytical procedures and their validations were reviewed and found to be adequate. Methods validation packages will not be sent to FDA laboratories because the methods do not meet the "method validation request criteria" according to the current ONDQA policy that was announced on 1/12/05.

***The proposed proprietary names were consulted to the Division of Medication Errors and Technical Support (DMETS) in the Office of Drug Safety (consults sent by Elaine Abraham, the Project Manager). At the completion of this CMC review, only the review of _____ by DMETS is in DFS (the consults for the remaining proprietary names were sent separately). The DMETS' 12/9/05 review states that DMETS does not recommend the use of the proprietary name _____. However, according to the 2/22/06 e-mail from Elaine Abraham, DMETS gave the Office of Nonprescription Drugs (ONP) the option of going with the names or not, during a recent meeting between DMETS and ONP. The ONP's decision can be seen in the 2/21/06 labeling review by Dr. Michael Koenig, the ONP labeling reviewer, which indicates that all the proposed trade names are acceptable (see page 3 of the labeling review).

b(4)

b(4)

APPEARS THIS WAY ON ORIGINAL

The Chemistry Review for NDA 21-501

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a chemistry review perspective, this NDA is approvable pending an acceptable recommendation from the Office of Compliance for the establishment inspections. As of this review, the inspection at _____ is still pending.

b(4)

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

(1) Drug Substances

The drug product contains three drug substances: avobenzone, ecamsule, and octocrylene. Avobenzone and octocrylene are active ingredients included in the over-the-counter (OTC) sunscreen monographs (21 CFR 352.10 and 352.20). These two drug substances are also USP monograph substances.

Ecamsule is a new molecular entity. It was included in the drug product in _____

b(4)

Detailed information on the drug substances is referenced to their respective DMFs, which have been reviewed by this reviewer and found to be adequate to support this NDA.

Executive Summary Section

(2) Drug Product

The drug product is a sunscreen containing 2% of avobenzone, 3% of ecamsule, and 10% of octocrylene. The active ingredients were selected to provide a broad protection from UVA (320 to 400 nm) and UVB (290 to 320 nm) irradiation wavelengths. The absorption bands are as follows: avobenzone from 320 to 400 nm, octocrylene from 250 to 370 nm, and ecamsule from 290 to 400 nm.

The drug product also contains — excipients that provide functions such as _____ This
sunscreen is water resistant due to _____

b(4)

b(4)

The drug product is packaged in a 100-mL tube with an HDPE head and a polypropylene snap-top closure.

B. Description of How the Drug Product is Intended to be Used

The drug product is intended to be applied topically for the prevention of sunburn. —
_____ due to chronic sun exposure. It is proposed to be available over-the-counter. b(4)
The sunscreen is applied 15 minutes before sun exposure. It may be reapplied as needed or after towel drying, swimming, or perspiring.

The sunscreen is to be stored at 20-25°C. The submitted drug product stability data include long-term stability data for _____ months and accelerated stability data for 6 months on three primary stability batches manufactured at the proposed commercial manufacturing site. An expiration dating period of 30 months is granted for the drug product based on the stability data. b(4)

Executive Summary Section

C. Basis for Approvability or Not-Approval Recommendation

The CMC information regarding the drug substance and drug product is adequate to support the over-the-counter use of this drug product, a sunscreen. The only pending issue is the establishment inspection.

The inspection of _____ which is one of the avobenzone drug substance manufacturing sites, is still pending. This NDA can not be approved without an "acceptable" recommendation from the Office of Compliance for all the manufacturing and control facilities. b(4)

Five proprietary names, for five different marketing divisions, are proposed in the NDA. The Office of Drug Safety has objections to the use of _____

_____ However, the Office of Non-prescription Drugs (ONP) has determined that all of the proposed proprietary names are acceptable. Refer to the 2/21/06 labeling review by the ONP reviewer Dr. Michael Koenig. b(4)

III. Administrative

- A. Reviewer's Signature electronically signed in DFS
- B. Endorsement Block electronically signed in DFS
- C. CC Block electronically signed in DFS

57 Page(s) Withheld

Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Sue Ching Lin
3/2/2006 04:22:43 PM
CHEMIST

Moo-Jhong Rhee
3/2/2006 04:54:32 PM
CHEMIST
Chief, Branch III